Locomotor activity changes in female adolescent and adult rats during repeated treatment with a cannabinoid or club drug.
Jenny L Wiley, Rhys L Evans, Darren B Grainger, Katherine L Nicholson
Pharmacological Reports 2011 DOI: 10.1016/s1734-1140(11)70627-2 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Preclinical experimental study Peer reviewed |
|---|---|
| Population | Female adolescent and adult rats |
| Interventions | Cocaine Ketamine 3 4-methylenedioxymethamphetamine (MDMA) Δ(9)-tetrahydrocannabinol (THC) |
| Dose | Cocaine 7 or 15 mg/kg; ketamine 3 or 10 mg/kg; MDMA 3, 10, or 30 mg/kg; THC 0.03, 0.1, 0.3, or 1 mg/kg |
| Duration | Two five-day dosing periods separated by a two-day break |
| Key findings | Cocaine increased locomotor activity across days in both adolescent and adult female rats, and ketamine produced progressive increases with repeated administration at both ages. MDMA increased then decreased activity under chronic dosing only in adolescent females, while tolerance to low-dose THC's initial stimulatory effect appeared at both ages. The authors argue age and sex strongly influence sensitization to some, but not all, of these drugs. |
Abstract
Adolescents and young adults of both sexes are the primary consumers of "club" drugs; yet, most of the mechanistic preclinical research in this area has been performed in adult male rodents. The purpose of this study was to evaluate the acute and repeated effects of drugs that are commonly abused by adolescents in female adolescent and adult rats in a rodent model of behavioral sensitization. During two five-day periods separated by a two-day break, rats were injected daily with saline or with one of the following drugs: cocaine (7 or 15 mg/kg), ketamine (3 or 10 mg/kg), 3,4-methylenedioxymethamphetamine (MDMA) (3, 10, or 30 mg/kg), or Δ(9)-tetrahydrocannabinol (THC) (0.03, 0.1, 0.3 or 1 mg/kg) and their locomotor activity was measured. Cocaine increased activity across days in both age groups. Whereas ketamine produced progressive increases in activity with repeated administration in rats of both ages, MDMA increased, and then decreased, activity in the chronic dosing regimen in female adolescents only. Tolerance to the initial stimulatory effects of low doses of THC was observed at both ages. The results with THC are similar to those obtained for male rats tested under identical conditions in a previous study; however, in contrast with the present results in females, male adolescent rats in the previous study failed to develop behavioral sensitization to ketamine. Together, these results suggest that age and sex strongly influence the progressive adaptive changes that occur with repeated administration of some, but not all, of these commonly abused substances.
Citations in the library
Cited by 11
- The abuse liability of ketamine: A scoping review of preclinical and clinical studies. Journal of Psychiatric Research May 1, 2022
- On the safety of repeated ketamine infusions for the treatment of depression: Effects of sex and developmental periods Neurobiology of Stress September 21, 2018
- Use and abuse of dissociative and psychedelic drugs in adolescence Pharmacology, Biochemistry, and Behavior January 27, 2021
- Lasting effects of repeated Δ9-tetrahydrocannabinol (THC) vapor inhalation during adolescence in male and female rats bioRxiv (Cold Spring Harbor Laboratory) September 25, 2018
- Differential behavioral effects of ketamine between adolescent and adult Sprague-Dawley rats VCU Scholars Compass 2013
and 6 more in the library
Cites 4
- Subanesthetic Effects of the Noncompetitive NMDA Antagonist, Ketamine, in Humans Archives of General Psychiatry March 1, 1994
- Age-dependent differences in sensitivity and sensitization to cannabinoids and 'club drugs' in male adolescent and adult rats. Addiction Biology September 2008
- Sex differences in the neurochemical and functional effects of MDMA in Sprague-Dawley rats. Psychopharmacology January 2007
- Age modulates the long-term but not the acute effects of the serotonergic neurotoxicant 3,4-methylenedioxymethamphetamine. Journal of Pharmacology and Experimental Therapeutics October 1, 1994